Your shopping cart is currently empty

H-1152 is a cell membrane-permeable and selective ROCK (Rho-kinase) inhibitor (Ki=1.6 nM) that increases neurite length in neuron-rich cultures and inhibits MARCKS Ser159 phosphorylation in LPA-stimulated neuronal cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 500 μg | $43 | - | In Stock | |
| 1 mg | Preferential | - | In Stock |
| Description | H-1152 is a cell membrane-permeable and selective ROCK (Rho-kinase) inhibitor (Ki=1.6 nM) that increases neurite length in neuron-rich cultures and inhibits MARCKS Ser159 phosphorylation in LPA-stimulated neuronal cells. |
| Targets&IC50 | Src:3.06 μM, AMPK:100 μM, ROCK2:12 nM, PKA:3.03 μM, Abl:7.77 μM, PKC:5.68 μM, MLCK:28.3 μM, GSK3α:60.7 μM, P38α:100 μM, MKK4:16.9 μM, Aurora A:0.745 μM, EGFR:50 μM, CaMK II:0.18 μM, PKG:0.36 μM |
| In vitro | H-1152 potently inhibits Rho kinase (Ki = 1.6 nM) while exhibiting only mild inhibitory effects on PKA, PKC, and MLCK with Ki values of 0.63 μM, 9.27 μM, and 10.1 μM, respectively. In LPA-treated cells, H-1152 (0.1-10 μM) significantly suppresses MARCKS protein phosphorylation with an IC₅₀ of 2.5 μM, whereas no such pronounced effect was observed in PDBu-treated cells [2]. H-1152 (0.5-10 μM) does not reduce neuronal viability. Neither does H-1152 (1, 5, or 10 μM) alter the proportion of different neuronal morphologies. Furthermore, in both BMP4 and LIF culture systems, H-1152 (10 μM) enhances neurite outgrowth length [3]. |
| Synonyms | H1152, H 1152 |
| Molecular Weight | 319.42 |
| Formula | C16H21N3O2S |
| Cas No. | 451462-58-1 |
| Smiles | S(=O)(=O)(C=1C2=C(C=CC1)C=NC=C2C)N3[C@@H](C)CNCCC3 |
| Relative Density. | 1.218 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (250.45 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (10.33 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.